New hope for lymphoma patients with Tough-to-Treat genetic flaw
NCT ID NCT07240194
Summary
This study is testing a new combination of three drugs (glofitamab, a PD-1 inhibitor, and lenalidomide) for patients with an aggressive type of lymphoma that has come back or not responded to prior treatment and has a specific genetic change called TP53. The main goal is to see if this combination can put the cancer into complete remission. The study will enroll 24 participants to evaluate how well the treatment works and how safe it is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.